rituximab for the treatment of patients with autoimmune hepatitis who are refractory or intolerant to standard therapy
Current Language EN
English English Türkçe Türkçe Español Español Português Português Pусский Pусский Filipino Filipino Tiếng Việt Tiếng Việt हिन्दी हिन्दी العربية العربية বাংলা বাংলা Deutsch Deutsch 中文 中文

rituximab for the treatment of patients with autoimmune hepatitis who are refractory or intolerant to standard therapy

;Kelly W Burak;Mark G Swain;Tania Santodomino-Garzon;Samuel S Lee;Stefan J Urbanski;Alexander I Aspinall;Carla S Coffin;Robert P Myers
indian journal of pharmacology 2013 Vol. 27 pp. 273-280
139
burak2013canadianrituximab

Abstract

BACKGROUND: Although most patients with autoimmune hepatitis (AIH) respond to treatment with prednisone and/or azathioprine, some patients are intolerant or refractory to standard therapy. Rituximab is an anti-CD20 monoclonal antibody that depletes B cells and has demonstrated efficacy in other autoimmune conditions.

Keywords

Gastroenterology diseases of the digestive system

Access

DOI:
10.1155/2013/512624
URL:
http://dx.doi.org/10.1155/2013/512624

Citation

ID: 186109
Ref Key: burak2013canadianrituximab
Use this key to autocite in SciMatic or Thesis Manager

References

References

No Bibliography

Blockchain Verification

Account:
NFT Contract Address:
0x95644003c57E6F55A65596E3D9Eac6813e3566dA
Article ID:
186109
Unique Identifier:
10.1155/2013/512624
Network:
Scimatic Chain (ID: 481)
Blockchain Readiness Checklist
Authors
Abstract
Journal Name
Year
Title
5/5
Creates 1,000,000 NFT tokens for this article
Token Features:
  • ERC-1155 Standard NFT
  • 1 Million Supply per Article
  • Transferable via MetaMask
  • Permanent Blockchain Record
Blockchain QR Code
Scan with Saymatik Web3.0 Wallet
Gas fees required in SCI Coins
Buy SCI

Saymatik Web3.0 Wallet

Google Play
App Store